HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for ...
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for ...
Bill Grossman is leaving Arcus Biosciences to take up a position at Gilead, putting him in charge of the Big Pharma's collaboration with his former employers. Grossman is currently chief medical ...
Gilead Sciences (GILD 2.18%) and Arcus Biosciences (RCUS 4.04%) have signed a 10-year agreement to co-develop and co-commercialize the next-generation cancer therapeutics in Arcus' pipeline. The ...
Arcus’s pipeline includes several promising candidates, including domvanalimab, an Fc-silent anti-TIGIT antibody, and zimberelimab, an anti-PD-1 antibody. Arcus recently announced positive results ...
New data from the Phase 1/1b ARC-20 cohort evaluating HIF-2a inhibitor casdatifan in combination with cabozantinib in clear cell renal cell carcinoma (ccRCC) will be presented in an oral session by Dr ...
Gilead Sciences Inc. is paying Arcus Bioscience Inc. $175 million up front, shelling out a $200 million equity investment, and pledging potentially $1.6 billion or more in the form of R&D support, opt ...
Arcus Biosciences aims to develop therapies that harness the immune system to fight cancer. Its research focuses on several new drug candidates that may improve outcomes for patients with cancers like ...
The transaction value is based on the SEC Form 4 weighted average purchase price ($20.76) for the trades executed. How significant was this sale relative to Jaen Juan C.'s historical trading? This was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results